Figure 2
Figure 2. Role of UGT2B17 in CLL susceptibility and drug response. (A) UGT2B17 genotype and CLL susceptibility and (B) change in UGT2B17 mRNA expression in CLL cells during treatment with fludarabine and cyclophosphamide.

Role of UGT2B17 in CLL susceptibility and drug response. (A) UGT2B17 genotype and CLL susceptibility and (B) change in UGT2B17 mRNA expression in CLL cells during treatment with fludarabine and cyclophosphamide.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal